Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspira Technologies Oxy BHN ( (IINN) ) just unveiled an announcement.
On July 31, 2025, Inspira Technologies announced the activation of a U.S.-based consulting firm to enhance its strategic expansion and partner engagement. This collaboration follows significant developments like major purchase orders and clinical integration of its ART100 system in U.S. hospitals, aiming to scale the company’s commercial platform and strengthen its position in the medtech ecosystem.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company’s products include the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and the HYLA blood sensor platform. Inspira Technologies is positioned within the life-support and MedTech landscape with a focus on strategic partnerships and industry trends.
Average Trading Volume: 926,348
Technical Sentiment Signal: Buy
Current Market Cap: $32.28M
For an in-depth examination of IINN stock, go to TipRanks’ Overview page.